Stockscreener 앱 받기
6.06
0.16%
-0.01
시간 외 거래:
6.05
-0.010
-0.17%
전일 마감가:
$6.07
열려 있는:
$6.05
하루 거래량:
1.76M
Relative Volume:
1.33
시가총액:
$277.04M
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-7.3012
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
-1.94%
1개월 성능:
-17.66%
6개월 성능:
-48.90%
1년 성능:
-67.41%
1일 변동 폭
$6.00
$6.41
1주일 범위
$6.00
$7.08
52주 변동 폭
$5.68
$20.75
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
CAPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.06 | 277.50M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Capricor Therapeutics, Inc. Long-Term Shareholder - GlobeNewswire
Capricor Therapeutics (CAPR) Projected to Post Quarterly Earnings on Monday - MarketBeat
What insider purchases suggest about Capricor Therapeutics Inc. (4LN2) stockQuarterly Market Summary & Low Risk High Reward Trade Ideas - newser.com
What valuation multiples suggest for Capricor Therapeutics Inc. stockRecession Risk & Target Return Focused Picks - newser.com
How high can Capricor Therapeutics Inc. stock go2025 Performance Recap & AI Powered Buy and Sell Recommendations - newser.com
Why Capricor Therapeutics Inc. stock is a must watch in 2025July 2025 Patterns & Fast Entry High Yield Tips - newser.com
Will Capricor Therapeutics Inc. stock benefit from upcoming earnings reportsMarket Activity Recap & Community Verified Watchlist Alerts - newser.com
Chart based analysis of Capricor Therapeutics Inc. trends2025 Technical Overview & Technical Pattern Based Signals - newser.com
What hedge fund moves indicate for Capricor Therapeutics Inc. (4LN2) stock2025 Year in Review & Proven Capital Preservation Tips - newser.com
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback - Stocktwits
Will Capricor Therapeutics Inc. (4LN2) stock announce a stock splitJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
Can Capricor Therapeutics Inc. stock hit analyst price targets2025 Market Overview & Weekly High Return Opportunities - newser.com
Capricor Therapeutics (CAPR) Advances DMD Treatment with New Res - GuruFocus
Strategies to average down on Capricor Therapeutics Inc.2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel - The Manila Times
Capricor Therapeutics Publishes Peer-Reviewed Study in - GlobeNewswire
Smart tools for monitoring Capricor Therapeutics Inc.’s price actionJuly 2025 Retail & AI Based Buy/Sell Signal Reports - newser.com
Is Capricor Therapeutics Inc. (4LN2) stock a momentum leader2025 Earnings Surprises & Low Risk Entry Point Guides - newser.com
Will Capricor Therapeutics Inc. price bounce be sustainableQuarterly Portfolio Review & Verified Momentum Watchlists - newser.com
Will Capricor Therapeutics Inc. (4LN2) stock outperform energy sector in 2025July 2025 Earnings & Trade Opportunity Analysis - newser.com
Price momentum metrics for Capricor Therapeutics Inc. explained2025 Trading Volume Trends & Long-Term Growth Stock Strategies - newser.com
What institutional flow reveals about Capricor Therapeutics Inc.July 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Capricor Therapeutics Inc.’s volatility index tracking explainedGap Up & Daily Growth Stock Tips - newser.com
Chart overlay techniques for tracking Capricor Therapeutics Inc.Weekly Trend Summary & Community Supported Trade Ideas - newser.com
Will Capricor Therapeutics Inc. (4LN2) stock see insider accumulationGlobal Markets & AI Forecast for Swing Trade Picks - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Is it too late to sell Capricor Therapeutics Inc.Market Movers & Community Driven Trade Alerts - newser.com
HBK Sorce Advisory LLC Increases Stake in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Capricor Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - newser.com
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 - The Manila Times
Capricor Therapeutics to Announce Third Quarter 2025 Financial Results on November 10, 2025 - Quiver Quantitative
Capricor (NASDAQ: CAPR) schedules financial results call for Nov 10 at 4:30 p.m. ET - Stock Titan
We're Hopeful That Capricor Therapeutics (NASDAQ:CAPR) Will Use Its Cash Wisely - Yahoo Finance
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):